Effect of imipramine on depression and immune status in a sample of men with HIV infection
Abstract
Eleven men with major depression and human immunodeficiency virus (HIV) infection underwent an open trial of imipramine. Eight of nine (89%) who completed 12 weeks responded. The mean decline in T4 cells from baseline was 100 at week 12 and 16 at week 26. No major exacerbations of HIV infection occurred.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
